1. Home
  2. MOJPB
  3. The controversial role of osteopontin in vascular calcification from bench to bedside
Submit manuscript...
MOJ
eISSN: 2374-6920

Proteomics & Bioinformatics

Short Communication Volume 5 Issue 4

The controversial role of osteopontin in vascular calcification: from bench to bedside

Alexander E Berezin

Department, of Internal Medicine, State Medical University, Ukraine

Correspondence: Alexander E Berezin, Professor, MD, PhD, Consultant of Therapeutic Unit, Private Hospital Vita Center, 3, Sedova str., Zaporozhye, Ukraine, Tel +380612894585

Received: March 28, 2017 | Published: April 27, 2017

Citation: Berezin AE. The controversial role of osteopontin in vascular calcification: from bench to bedside. MOJ Proteomics Bioinform. 2017;5(4):129-130. DOI: 10.15406/mojpb.2017.05.00167

Download PDF

Abstract

Osteopontin (OPN) is integrin-binding ligand belonged to the family of N-linked glycoprotein, which is produced by activated mononuclears and linking systemic inflammation, atherosclerosis, and vascular remodeling. There is a large body of evidence regarding the controversial role of OPN in vascular calcification, while OPN is considered a pretty accurate biomarker of vascular remodeling with promising predictive value for cardiovascular (CV) disease and CV events. The short communication is depicted the discussion about some controversies regarding exclusive role of OPN in several phases of vascular remodeling.

Keywords: hypertension, vascular remodeling, inflammation, calcification, osteopontin, regulation

Short communication

Recent preclinical and clinical studies have shown that vascular calcification is inexorable pathological process leading to mechanical rigidity and stiffness of vascular wall, endothelial dysfunction, development and accelerating atherosclerosis even in the absence of established cardiovascular (CV) disease.1–3 Ectopic calcification is represented several mutually counteracting molecular mechanisms, i.e. oxidative stress, microvascular inflammation, immune cell-to-cell cooperation, accumulation of lipids and extracellular proteins, vascular reparative systems, and metabolic disorders.4–6 All these processes are under tight regulation of vitamin D, parathyroid hormone-related peptides (fibroblast growth factor, transcription factor Sox2, beta-catenin, etc) and matricellular proteins such as osteopontin (OPN).7–9

OPN is an integrin-binding ligand belonged to the family of N-linked glycoprotein, which is produced by activated mononuclears and linking systemic inflammation, atherosclerosis, and vascular remodeling via regulating ectopic calcification and extracellular matrix accumulation.10 The role of OPN in vascular calcification is pretty controversial. The first controversy is based on opinion regarding that the OPN was found in elevated concentration in patients with established vascular calcification, atherosclerosis, and CV disease associated with severe vascular remodeling including hypertension, chronic kidney disease, diabetes mellitus.4,9,11 In this context, OPN is an accurate biomarker of vascular remodeling closely relating to inflammation intensity, glucose level and pro-thrombotic state with promising predictive value for CV events.12

However, there is large body of evidence that OPN could be an inducible inhibitor of vascular calcification in vivo and that the elevation of OPN level in serum reflects an involvement of protective mechanisms against ectopic calcium deposition.13 Indeed, OPN deficiency may attenuate development and accelerating atherosclerosis increasing susceptibility to calcium deposition in smooth muscle cells.14,15

Second controversy relates to a widely known fact regarding that the OPN is strongly induced in mononuclear and myeloid cells acting as pro-inflammatory mediator of direct and indirect vascular injury leading to endothelial dysfunction.9,16,17 Interestingly, exogenous OPN is able to inhibit a differentiation of activated macrophages into osteoclasts in vascular wall and attenuate shaping M2-phenotype of macrophages with anti-inflammatory ability.9 Thus, mononuclears obtained from patients with and without established vascular calcification may reply to OPN in different way that confirms being alternatively shaping mononuclears in vascular wall during ectopic calcification. Probably, OPN exerts a pivotal role in turning M1 phenotype of macrophages into M2 phenotype in vascular calcification that coordinates reducing expression of several pro-inflammatory factors and attenuating vascular osteoclast formation.

The next controversy allows us considering about a cause of interrelationship between inflammatory cytokines, overproduction of reactive oxygen species and OPN expression in individuals with established CV diseases. Inflammatory-induced OPN through NADPH oxidase signaling cascade may regulate an activation of pro-matrix metalloproteinase 9 in aortic mesenchymal cells, which play a central role in vascular reparation18 acting as endogenous repair system together endothelial progenitor cells.6 Moreover, deficiency of OPN presentation in aorta associated with increased risk of aneurism formation, thrombosis and fissuring plaque cap.19 Whether OPN is a primary regulator of exaggerated inflammation cascade in the target cells via control of proliferative response or non-specific messenger, which protects vascular wall against calcium deposition through blockage of tissue metalloproteinases is not fully understood. However, there is evidence that inhibition of OPN prevented vascular calcification.20 How similar evidence relates to clinical findings regarding predictive value of circulating OPN in individuals with and without established CV diseases is not clear.21 Large clinical studies are required in future to explain in details the role of OPN as a biomarker of CV events and CV diseases and as well as a possible target of medical care.

Conclusion

OPN is considered a multi-directed factor contributing in several phases of vascular remodeling including calcium accumulation, atherosclerosis, vascular reparation and microvascular inflammation. The role of OPN as a pretty accurate biomarker of CV risk, CV diseases and CV events are actively investigated, while there are several controversies in final effects of OPN regarding vascular calcification based on multimodal pathogenetic capabilities of the molecule. Future investigations are needed to understand the possible role of OPN in biomarker-guided therapy of the CV disease and assay of vascular remodeling risk

Acknowledgements

None.

Conflict of interest

The author declares no conflict of interest.

References

  1. Shao JS, Sierra OL, Cohen R, et al. Vascular calcification and aortic fibrosis: a bifunctional role for osteopontin in diabetic arteriosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(8):1821–1833.
  2. Tesauro M, Mauriello A, Rovella V, et al. Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med. 2017;281(5):471–482.
  3. Berezin AE, Kremzer AA. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis. 2013;229(2):475–481.
  4. Berezin AE, Kremzer AA, Berezina TA, et al. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis. Acta Clin Belg. 2016;71(1):38–45.
  5. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, et al. Osteogenesis associates with inflammation in early–stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2017;116(24):2841–2850.
  6. Berezin AE. Endothelial progenitor cells dysfunction and impaired tissue reparation: The missed link in diabetes mellitus development. Diabetes Metab Syndr. 2017;11(3):215–220.
  7. Amizuka N, Davidson D, Liu H, et al. Signalling by fibroblast growth factor receptor 3 and parathyroid hormone–related peptide coordinate cartilage and bone development. Bone. 2004;34(1):13–25.
  8. Wolak T. Osteopontin–a multi–modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014;236(2):327–337.
  9. Ge Q, Ruan CC, Ma Y, et al. Osteopontin regulates macrophage activation and osteoclast formation in hypertensive patients with vascular calcification. Sci Rep. 2017;7:40253.
  10. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009;11(3):206–213.
  11. Stępień E, Wypasek E, Stopyra K, et al. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem. 2011;44(10–11):826–831.
  12. Berezin AE. Biomarkers for cardiovascular risk in patients with diabetes. Heart. 2016;102(24):1939–1941.
  13. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein–deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 2002;196(8):1047–1055.
  14. Matsui Y, Rittling SR, Okamoto H, et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E–deficient mice. Arterioscler Thromb Vasc Biol. 2003;23(6):1029–1034.
  15. Speer MY, Chien YC, Quan M, et al. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res. 2005;66(2):324–333.
  16. Berezin AE, Kremzer AA, Berezina TA, et al. Data regarding association between serum osteoprotegerin level, numerous of circulating endothelial–derived and mononuclear–derived progenitor cells in patients with metabolic syndrome. Data Brief. 2016;8:717–722.
  17. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol. 2010;7(9):528–536.
  18. Lai CF, Seshadri V, Huang K, et al. An osteopontin–NADPH oxidase signaling cascade promotes pro–matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res. 2006;98(12):1479–1489.
  19. Bruemmer D, Collins AR, Noh G, et al. Angiotensin II–accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin–deficient mice. J Clin Invest. 2003;112(9):1318–1331.
  20. Yao Y, Bennett BJ, Wang X, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010;107(4):485–494.
  21. Berezin AE. Bone–Related Proteins as Markers in Vascular Remodeling. In: Biomarkers in Bone Disease: Methods, Discoveries and Applications. Preedy VR, editor. Switzerland: Springer; 2016.
Creative Commons Attribution License

©2017 Berezin. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.

Citations

Journal Menu

Useful Links